Expands company’s already strong presence in Eastern Europe
WILMINGTON, N.C.--(BUSINESS WIRE)-- PPD, Inc. (Nasdaq: PPDI) today announced it has opened an office in Novosibirsk, Russia, building on the growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location.
The new office strengthens PPD’s presence in Russia, a country where it already has offices in Moscow, Smolensk and St. Petersburg. PPD is one of the largest CROs operating in Central and Eastern Europe, an important, high-growth market for clinical trials that offers efficient access to patients and a well-developed, centralized health care system.
"Establishing a presence in Novosibirsk allows us to serve clients more effectively and keep pace with clinical trial growth in this region,” said Roger Newbery, vice president of clinical development for Europe, Middle East and Africa. “This expansion provides us the ability to reach more than five million people and grow our number of investigator sites to meet growing client demand.”
The office is located at 2 Dimitrova Prospect, Novosibirsk 630099, Russia. For more information about PPD services provided from the Novosibirsk office, call +44 1223 374430.
PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 42 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the opening of an office in Novosibirsk, Russia, and its contributions to PPD, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with acquisitions and investments, such as impairments; success in sales growth; loss of large contracts; increased cancellation rates; rapid technological advances that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
CONTACT:
PPD, Inc.
Media:
Sue Ann Pentecost, 919-456-5890
[email protected]
Analysts/Investors:
Luke Heagle, 910-558-7585
[email protected]
KEYWORDS: United States Europe North America Russia North Carolina
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Clinical Trials Infectious Diseases Medical Devices Pharmaceutical Diabetes FDA
MEDIA:
| Logo |